Karyopharm Therapeutics Inc. (KPTI) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-05-26

Karyopharm Therapeutics Inc. (KPTI) has filed 13 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-26. 2 Form 8-K material event filings were reported by KPTI in the last 90 days. InsiderAlpha tracks every KPTI SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Karyopharm Therapeutics Inc. (KPTI)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001503802

90-Day SEC Filing Activity

Form 4 filings (90d)	13
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-05-26

Recent KPTI Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-21	Su Zhen	Insider	A — Grant or award	15.5K	$0.00	—	SEC
2026-05-21	PAKIANATHAN DEEPIKA	Insider	A — Grant or award	15.5K	$0.00	—	SEC
2026-05-21	Greene Barry E	Insider	A — Grant or award	15.5K	$0.00	—	SEC
2026-05-21	Oliger Christy J.	Insider	A — Grant or award	15.5K	$0.00	—	SEC
2026-05-21	Schor Chen	Insider	A — Grant or award	15.5K	$0.00	—	SEC
2026-05-21	BOHLIN GAREN G	Insider	A — Grant or award	15.5K	$0.00	—	SEC
2026-05-14	Paulson Richard A.	President and CEO	S — Open-market sale	2.2K	$9.50	$21K	SEC
2026-05-14	Poulton Stuart	EVP, Chief Development Officer	S — Open-market sale	403	$9.50	$4K	SEC
2026-05-14	Mano Michael	EVP, CLO&Secretary	S — Open-market sale	266	$9.50	$3K	SEC
2026-05-14	Cheng Sohanya Roshan	EVP & Chief Commercial Officer	S — Open-market sale	324	$9.50	$3K	SEC
2026-05-14	Rangwala Reshma	EVP & Chief Medical Officer	S — Open-market sale	408	$9.50	$4K	SEC
2026-05-14	Abate Kristin	Chief Accounting Officer	S — Open-market sale	53	$9.50	$504	SEC
2026-05-13	Paulson Richard A.	President and CEO	A — Grant or award	4.9K	$0.00	—	SEC
2026-05-13	Poulton Stuart	EVP, Chief Development Officer	A — Grant or award	896	$0.00	—	SEC
2026-05-13	Cheng Sohanya Roshan	EVP & Chief Commercial Officer	A — Grant or award	947	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Karyopharm Therapeutics Inc. (KPTI). Updated in real time as new filings are submitted to the SEC.

Most-Active KPTI Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Rangwala Reshma	3	$8K
Paulson Richard A.	2	$21K
Mano Michael	2	$3K
Poulton Stuart	2	$4K
Cheng Sohanya Roshan	2	$3K

Recent KPTI Form 8-K Material Events

2026-05-28 — Item 5.02, 5.07, 9.01 [SEC]
2026-05-14 — Item 2.02, 9.01 [SEC]
2026-03-27 — Item 8.01 · Financing · mixed [SEC]
Karyopharm completed a $30 million private placement with RA Capital Management involving common stock, pre-funded warrants, and accompanying warrants, along with $19.8 million in concurrent ATM sales. The combined ~$50 million in gross proceeds extends the company's cash runway
2026-03-24 — Item 1.01, 3.02, 7.01, 8.01, 9.01 · Financing · positive [SEC]
Karyopharm Therapeutics entered into a Securities Purchase Agreement with RA Capital Management on March 24, 2026, to raise approximately $30 million in gross proceeds through a private placement of common stock, pre-funded warrants, and common stock warrants, with potential for
2026-03-24 — Other · neutral [SEC]
Trading halt (T1) for KPTI. KPTI

Recent Insider Filings

2026-05-26 — Oliger Christy J. (Insider)
2026-05-26 — PAKIANATHAN DEEPIKA (Insider)
2026-05-26 — Schor Chen (Insider)
2026-05-26 — Su Zhen (Insider)
2026-05-26 — BOHLIN GAREN G (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in KPTI insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

KPTI Insider Trading — FAQ

What is the latest insider trade for KPTI?: Karyopharm Therapeutics Inc. (KPTI) had 13 insider filings in the last 90 days, with the most recent on 2026-05-26. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying KPTI stock?: 0 insider purchases of KPTI were filed in the last 90 days.
How many insiders are selling KPTI stock?: 0 insider sales of KPTI were filed in the last 90 days.
Where can I see KPTI SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every KPTI SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live KPTI dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.